Interestingly, the increased expression of the leucine-rich repeat kinase 2 (LRRK2) in CD8+ T lymphocytes from PD patients correlated with an increased secretion of pro-inflammatory molecules and cell activation, suggesting that LRRK2 may represent a therapeutic target in PD (137). The gene discussed is CD8A; the disease is Parkinson disease.